NVSNovartis AG
What is the market doing?
No clear lean: rangebound and a token position.
Choppy, but holding above its 200-day average. Overbought (RSI 71). Price is +1% vs its 200-day average.
A token position, settled Sep 30, 2026, a few days of normal trading to cover. Up 8.2% since the previous count, unchanged over three months.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How NVS is trading
Novartis AG is +19% over the past year while the S&P 500 is +16%: 3.1 points ahead of the market.
1-year return · S&P 500 +16%
- vs 200-day average
- +0.74%
vs 200-day average · close to trend
- RSI (14)
- 71
RSI (14) · overbought, bought harder than it has been sold
- Below its 52-week high
- 7.7%
Below its 52-week high
Details›
- Last close2026-10-23
- $151.11
- 1 monthS&P 500 −0.94%
- +5.3%
- 1 yearS&P 500 +16%
- +19%
- 5 yearsS&P 500 +86%
- +121%
- vs 50-day average$147.87
- +2.2%
- 52-week high
- $163.64
- 52-week low
- $118.20
- Annualised volatility
- 24%
| Year | Return |
|---|---|
| 2026 (year to date) | +13% |
| 2025 | +47% |
| 2024 | +0.02% |
| 2023 | +16% |
| 2022 | +8.1% |
| 2021 | −3.7% |
| 2020 | +3.3% |
| 2019 | +27% |
| 2018 | +5.9% |
| 2017 | +19% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 6 of 10 | +2.4% |
| Feb | 10 | 5 of 10 | −0.51% |
| Mar | 10 | 7 of 10 | +3.1% |
| Apr | 10 | 6 of 10 | +0.73% |
| May | 10 | 8 of 10 | +2.1% |
| Jun | 10 | 8 of 10 | +2.3% |
| Jul | 11 | 9 of 11 | +1.4% |
| Aug | 11 | 3 of 11 | +0.01% |
| Sep | 11 | 6 of 11 | −2.0% |
| Oct | 11 | 5 of 11 | −2.3% |
| Nov | 10 | 7 of 10 | +4.1% |
| Dec | 10 | 7 of 10 | +1.6% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.
Drug Manufacturers, General
Ranks #2 of 7 by RyuScore